Free Motion for Miscellaneous Relief - District Court of Delaware - Delaware


File Size: 20.0 kB
Pages: 2
Date: August 25, 2008
File Format: PDF
State: Delaware
Category: District Court of Delaware
Author: unknown
Word Count: 427 Words, 2,942 Characters
Page Size: Letter (8 1/2" x 11")
URL

https://www.findforms.com/pdf_files/ded/35784/41-2.pdf

Download Motion for Miscellaneous Relief - District Court of Delaware ( 20.0 kB)


Preview Motion for Miscellaneous Relief - District Court of Delaware
Case 1:05-cv-00854-JJF

Document 41-2

Filed 08/25/2008

Page 1 of 2

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE BOEHRINGER INGELHEIM INTERNATIONAL ) GMBH and BOEHRINGER INGELHEIM ) PHARMACEUTICALS, INC., ) ) Plaintiffs, ) ) v. ) ) BARR LABORATORIES, INC., ) ) Defendant. ) __________________________________________) ) BOEHRINGER INGELHEIM INTERNATIONAL ) GMBH and BOEHRINGER INGELHEIM ) PHARMACEUTICALS, INC., ) ) ) Plaintiffs, ) ) v. ) ) MYLAN PHARMACEUTICALS, INC., ) ) Defendant. ) __________________________________________)

C.A. No. 05-700-JJF CONSOLIDATED

C.A. No. 05-854-JJF

FINAL JUDGMENT ORDER WHEREAS, in consolidated actions (Civil Action No. 05-700-(JJF) and Civil Action No. 05-854-(JJF)), Plaintiffs Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. ("Boehringer") asserted that: (1) Defendant Barr Laboratories, Inc.'s Abbreviated New Drug Application ("ANDA") No. 77724 for generic pramipexole dihydrochloride tablets infringed certain claims of U.S. Patent No. 4,843,086 ("the '086 patent") and U.S. Patent No. 4,886,812 ("the '812 patent"); and (2) Defendant Mylan Pharmaceuticals Inc.'s ANDA No. 77-854 for generic pramipexole dihydrochloride tablets infringed certain claims of the '812 patent;

Case 1:05-cv-00854-JJF

Document 41-2

Filed 08/25/2008

Page 2 of 2

WHEREAS the '086 patent expired on June 27, 2006; WHEREAS Defendant Barr Laboratories, Inc.'s counterclaim that the '812 patent is unenforceable was dismissed per stipulation of the parties on November 5, 2007 (D.I. 177); WHEREAS these consolidated actions having come to trial in March 2008 before this Court, the Honorable Joseph J. Farnan, Jr., District Judge, presiding, and the remaining issues having been tried, and the Court having issued its Memorandum Opinion on June 26, 2008; and WHEREAS Boehringer and Defendant Barr Laboratories, Inc. have agreed to settle Civil Action No. 05-700 (JJF) and have filed a Stipulation And Order Of Dismissal (D.I. 258); NOW THEREFORE, IT IS ORDERED AND ADJUDGED for the reasons set forth in the Court's Memorandum Opinion dated June 26, 2008, that: 1. Claims 3, 4, 5, 7, 9 and 10 of the '812 patent are invalid on the ground of

nonstatutory double patenting; 2. Judgment is entered in favor of Defendant Mylan Pharmaceuticals Inc. ("Mylan")

and against Boehringer on Mylan's counterclaim that Claims 3, 4, 5, 7, 9 and 10 of the '812 patent are invalid on the ground of nonstatutory double patenting; and 3. Judgment is entered in favor of Mylan and against Boehringer on Boehringer's

claims of infringement and Mylan's counterclaim of noninfringement because Claims 5, 7, 9 and 10 of the '812 patent, the claims asserted by Boehringer, are invalid on the ground of nonstatutory double patenting.

SO ORDERED this ______ day of August, 2008.

_______________________________ The Honorable Joseph J. Farnan, Jr. United States District Judge 2